Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naive (TN) older patients (≥65 years) and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We now report on long-term efficacy and safety with median follow-up of 5 years in this patient population with TN (N=31) and R/R […]
Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Read More »
